Your session is about to expire
← Back to Search
Other
Citicoline Supplement for Alzheimer's Disease
N/A
Recruiting
Led By Victoria Pak, PhD, MS, MTR
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
At least 18 years of age living within the continental United States
Participants who are diagnosed with AD and confirmed from the medical record
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 3 months
Awards & highlights
Study Summary
This trial is testing whether a dietary supplement called citicoline will improve sleep and cognition in people with Alzheimer's disease. Citicoline has been shown to be well tolerated in previous studies.
Who is the study for?
This trial is for adults with Alzheimer's Disease living in the continental U.S. who can read English and have internet access. It excludes those with severe health issues like heart failure, diabetes type I, liver cirrhosis; psychiatric disorders; sleep apnea; or a history of substance abuse.Check my eligibility
What is being tested?
The study tests if a citicoline dietary supplement improves sleep and cognition in Alzheimer's patients compared to a placebo. Citicoline has shown promise in previous studies for cognitive decline and is considered well-tolerated.See study design
What are the potential side effects?
Citicoline is generally well tolerated by individuals with Alzheimer's disease at the tested dosage. Specific side effects are not listed but may include mild gastrointestinal symptoms based on general knowledge of supplements.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 or older and live in the continental US.
Select...
I have been diagnosed with Alzheimer's disease, confirmed by my medical records.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in the impact on daytime sleepiness by the administration of the citicoline supplement.
Change in the impact on sleep by the administration of the citicoline supplement.
Secondary outcome measures
To examine how a change in sleep correlates with changes in cognitive function with the administration of citicoline.
To examine how a change in sleep correlates with changes in executive functioning with the administration of citicoline.
To examine how a change in sleep correlates with changes in memory function with the administration of citicoline.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Citicoline SupplementExperimental Treatment1 Intervention
Participants with AD will receive a dietary citicoline supplement
Group II: PlaceboPlacebo Group1 Intervention
Participants with AD will receive a placebo supplement
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Citicoline supplement
2018
N/A
~310
Find a Location
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,640 Previous Clinical Trials
2,560,676 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,675 Previous Clinical Trials
28,020,865 Total Patients Enrolled
Goizueta Alzheimer's Disease Research Center (ADRC)UNKNOWN
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 or older and live in the continental US.I have been diagnosed with Alzheimer's disease, confirmed by my medical records.You have a history of depending too much on alcohol or misusing medications.I have a chronic condition like heart failure, diabetes, or arthritis.You work night shifts, travel across time zones frequently, or have an irregular work schedule that may affect your body's natural rhythms.I have had epilepsy or a head injury causing unconsciousness in the last 2 years.
Research Study Groups:
This trial has the following groups:- Group 1: Citicoline Supplement
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants has the research team recruited for this project?
"Affirmative. Clinicaltrials.gov indicates that this research trial, which was initially posted on July 27th 2022, is still actively seeking participants. The current goal is to enroll 20 individuals from two different medical facilities."
Answered by AI
Are there any available spaces for participants in this research endeavor?
"Per the details available on clinicaltrials.gov, this research is currently enrolling participants and has been since its original posting date of July 27th 2022 - no updates have taken place in the interim."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger